<DOC>
	<DOC>NCT00651599</DOC>
	<brief_summary>Study to demonstrate that the therapeutic efficacy of AngeliqÂ® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.</brief_summary>
	<brief_title>Treatment of Vasomotor Symptoms in Korean Post Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<criteria>Postmenopausal Korean women suffering from hot flushes Standard exclusion criteria for HRT clinical trials had to be obeyed, including current or history of hormone dependent malignant disease, thromboembolic disorders, abnormal cervical smear, undiagnosed vaginal bleeding.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vasomotor symptoms</keyword>
	<keyword>Vasomotor System</keyword>
</DOC>